Climb Bio Completes Transition To Immune-mediated Disease Focused Company; Expects Cash Runway Through 2027 To Enable Delivery Of Key Value Inflection Points
Climb Bio Completes Transition To Immune-mediated Disease Focused Company; Expects Cash Runway Through 2027 To Enable Delivery Of Key Value Inflection Points
Climb Bio完成向免疫介導疾病專注公司的轉型；預計現金儲備可支持至2027年，實現關鍵價值拐點的交付
Climb Bio Completes Transition To Immune-mediated Disease Focused Company; Expects Cash Runway Through 2027 To Enable Delivery Of Key Value Inflection Points
Climb Bio完成向免疫介導疾病專注公司的轉型；預計現金儲備可支持至2027年，實現關鍵價值拐點的交付
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。